Advanced search
Publication Cover
Modern Rheumatology Volume 23, 2013 - Issue 4
Journal homepage
482
Views
84
CrossRef citations to date
0
Altmetric
Case Report

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

Manabu ArakiMultiple Sclerosis Center, National Center Hospital, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira 187-8551, Japan
,
Toshimasa AranamiDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan
,
Takako MatsuokaDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan
,
Masakazu NakamuraDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan
,
Sachiko MiyakeDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan
&
Takashi YamamuraMultiple Sclerosis Center, National Center Hospital, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira 187-8551, Japan;Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, JapanCorrespondence[email protected]
Pages 827-831 | Received 16 May 2012, Accepted 21 Jun 2012, Published online: 02 Jan 2014

REFERENCES

  • Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuro-myelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–12.
  • Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, and Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aqu-aporin-4 water channel. J Exp Med 2005;202:473–7.
  • Lucchinetti CF, Mandler RN, McGovern D, Bruck W, Gleich G, Ransohoff RM. A role for humoral mechanisms in the patho-genesis of Devic's neuromyelitis optica. Brain. 2002;125: 1450–61.
  • Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Pa-padopoulos MS. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromy-elitis optica lesions in mice. Brain. 2010;133:349–611.
  • Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: pathogenicity of patients immuno-globulin in vivo. Ann Neurol. 2009;66:630–43.
  • Okamoto T, Ogawa M, Lin Y, Murata M, Miyake S, Yamamura T. Review: treatment of neuromyelitis optica: current debate. Ther Adv Neurol Dis. 2008;1:43–52.
  • Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, Date H, et al. IFN/3- lb may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75: 1423–7.
  • Kleiter I, Hellwig K, Berthele A, Kumpfel T, Linker RA, Harting H-P, et al. Failure of natalizumab to prevent relapses in neuro-myelitis optica. Arch Neurol. 2012;69:239–45.
  • Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012; 18:113–5.
  • Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 1270–2.
  • Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al. Interleukin 6 signaling promotes anti-aquaporin 4 auto-antibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA. 2011;108:3701–6.
  • Yoshizaki K, Nakagawa T, Kaieda T, Muraguchi A, Yamamura Y, Kishimoto T. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. J Immunol. 1982;128:1296–301.
  • Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol. 2012;52: 199–219.
  • Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–9.
  • Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.
  • McCaffery M, Beebe A, editors. Pain: clinical manual for nursing practice. Baltimore: Mosby; 1993.
  • Imura T, Takaso M, Nakazawa T, Naruse K, Takahira N, Itoman M. Correlation between inflammatory cytokines in the spinal fluid and spinal disorders. J Lumber Spine Disord. 2008;14: 134–9.
  • Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathogenic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112: 3959–64.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.